The National Institute of Neurological Disorders and Stroke (NINDS) has awarded a 3-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital to fund completion of preclinical studies, manufacturing and preparation of an IND application for a first-in-human trial to advance adeno-associated virus (AAV)-ATP7A gene therapy for the treatment of Menkes disease.
Everzom SAS, a CNRS/Université Paris Cité spin-off, has signed a second exclusive license agreement with Erganeo SAS for the development of Evergel, an exosome drug candidate for fistulas and fibrosis of the digestive tract.
Eilean Therapeutics LLC has announced the acquisition of Ness Therapeutics Inc. in an all-equity transaction, including Ness’ best-in-class tyrosine-protein phosphatase non-receptor type 2 (PTPN2) inhibitors with application in immuno-oncology.
A male patient who harbored a deletion in the intron 7-exon 8 region of the dystrophin gene, DMD, was showing symptoms that matched with Becker muscular dystrophy.
Biomunex Pharmaceuticals SAS has signed an exclusive license and exploitation agreement with Institut Curie for the development of a new class of antibodies.
Scientists from Sun Yat-sen University Cancer Center (SYSUCC) and affiliated organizations have reported data from a study that assessed the role of discs large-associated protein 5 (DLGAP5) in lung adenocarcinoma (LUAD).
Fibrocor Therapeutics Inc. has entered into a research and development collaboration with the Mcquade Center for Strategic Research and Development LLC (MSRD).
Organoids are 3D models created from human stem cells and resemble fetal tissues. In an article published in Nature Medicine on March 4, 2024, researchers from University College London provided details on the possibility of generating organoids from epithelial cells collected from amniotic fluid without terminating the pregnancy.
RSS
